Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
204 studies found for:    Open Studies | "Hodgkin Disease"
Show Display Options
Rank Status Study
1 Not yet recruiting A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Condition: Hodgkin Disease
Interventions: Drug: Brentuximab vedotin;   Drug: Doxorubicin;   Drug: Vinblastine;   Drug: Dacarbazine
2 Recruiting Brazilian Prospective Hodgkin Lymphoma Registry
Conditions: Hodgkin Lymphoma;   Hodgkin Disease
Intervention:
3 Recruiting Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
Condition: Hodgkin's Disease
Intervention:
4 Recruiting Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE
Condition: Hodgkin Disease
Interventions: Drug: Brentuximab Vedotin;   Drug: Etoposide;   Drug: Carboplatine;   Drug: Ifosfamide
5 Not yet recruiting A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response
Condition: Hodgkin Disease
Interventions: Biological: Nivolumab;   Biological: brentuximab vedotin;   Biological: bendamustine
6 Recruiting A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Condition: Hodgkin Disease
Interventions: Drug: brentuximab vedotin;   Drug: bendamustine;   Drug: dacarbazine;   Drug: nivolumab
7 Recruiting Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
Condition: Hodgkin Disease
Interventions: Drug: ABVE-PC;   Drug: DECA
8 Recruiting Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin's Disease
Intervention:
9 Recruiting Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Stanford V Chemotherapy;   Radiation: Radiation Therapy
10 Recruiting Brentuximab for Newly Diagnosed Hodgkin Disease
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Rituximab
11 Recruiting Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Adriamycin;   Drug: Dacarbazine
12 Recruiting A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab Vedotin
13 Recruiting Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: Temsirolimus
14 Recruiting HD17 for Intermediate Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);   Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine);   Radiation: 30Gy IF-RT (Involved-Field Radiotherapy);   Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)
15 Recruiting GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: AFM13
16 Recruiting Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
17 Recruiting Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
Condition: Hodgkins Lymphoma
Intervention: Biological: allogeneic donor derived LMP specific cytotoxic T-lymphocyte
18 Recruiting Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma
Condition: Classical Hodgkin Lymphoma
Intervention: Other: Digital Polymerase Chain Reaction
19 Recruiting Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
Condition: Hodgkins Lymphoma
Intervention: Biological: Avelumab
20 Recruiting Genetic Study of Families With High Frequency of Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.